Does Geisinger Health Plan Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 receptor alpha subunit, interrupting IL-4 and IL-13 signaling simultaneously. The FDA approved dupilumab first for moderate-to-severe atopic dermatitis in adults in March 2017, and the label has since expanded to cover adolescents and children as young as 6 months, moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, prurigo nodularis, and, most recently, COPD with type-2 inflammation. See the current FDA prescribing information.

Why the Price Tag Triggers Prior Authorization

The list price of Dupixent is approximately $35,000 to $40,000 per year before rebates, placing it firmly in the specialty drug category. Specialty drugs routinely require prior authorization because plans negotiate rebates tied to utilization management. Step therapy policies, which require cheaper alternatives first, are standard across most commercial and Medicaid managed care plans, including those administered by Geisinger Health Plan.

Clinical Efficacy That Justifies Coverage Requests

When building a coverage argument, citing trial data helps. In the key SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks achieved an IGA 0/1 response ("clear or almost clear skin") in 37-38% of adults versus 8-10% for placebo at 16 weeks (P<0.001). PubMed PMID 26836809 Pruritus NRS scores fell by roughly 40% from baseline in treated patients. These are outcomes that topical corticosteroids and calcineurin inhibitors rarely replicate in moderate-to-severe disease, a fact your prescriber can document in the prior authorization letter.

Geisinger Health Plan: Plan Types and Formulary Structure

Geisinger Health Plan is a regional managed care organization headquartered in Danville, Pennsylvania. It operates several distinct product lines, and coverage rules differ across them.

Commercial Plans

Commercial members (employer-sponsored or individual market) face the most variable benefit designs. Dupixent typically lands on a specialty tier with a per-fill coinsurance of 20-35% before the out-of-pocket maximum is reached. The specialty tier often has a separate deductible or requires the member to use a specialty pharmacy network. Most commercial plans require prior authorization.

Medicare Advantage Plans

Geisinger Gold Medicare Advantage products follow CMS Part D specialty drug rules. Dupixent falls under Part B when administered in a physician's office (as a subcutaneous injection the patient administers at home, it usually falls under Part D). Under Part D, dupilumab is subject to the catastrophic coverage threshold. Starting in 2025, the Inflation Reduction Act caps Medicare Part D out-of-pocket costs at $2,000 per year, which substantially reduces cost-sharing for high-cost biologics. CMS IRA Part D changes

Medicaid Managed Care (Geisinger Health Plan for Pennsylvania HealthChoices)

Pennsylvania HealthChoices, the state's Medicaid managed care program, contracts with plans including Geisinger. Pennsylvania Medicaid must cover all FDA-approved drugs, but plans may impose prior authorization. State Medicaid rules limit step therapy to documented, clinically appropriate alternatives. If a prescriber certifies that alternatives are contraindicated or clinically inappropriate, the plan generally cannot enforce step therapy under Pennsylvania Medicaid policy.

Prior Authorization Requirements for Dupixent Under Geisinger

Prior authorization (PA) is the single biggest barrier to Dupixent access. Geisinger, like most plans, uses a set of clinical criteria derived largely from the FDA label and the American Academy of Dermatology (AAD) guidelines.

Standard Clinical Criteria

The AAD's 2023 guidelines on atopic dermatitis state: "Dupilumab is recommended for patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies." (AAD Guidelines, JAmAcadDermatol 2023) Geisinger's PA criteria for dupilumab in atopic dermatitis typically require:

• A confirmed diagnosis of moderate-to-severe atopic dermatitis, often quantified by an Investigator's Global Assessment (IGA) score of 3 or 4 or an Eczema Area and Severity Index (EASI) score above 16.
• Documented trial and failure of at least one topical corticosteroid of medium-to-high potency used for a minimum of 4-6 weeks.
• Documentation that cyclosporine, methotrexate, or another systemic agent was either tried and failed or is contraindicated (criteria vary by plan year).
• Prescription by or in consultation with a board-certified dermatologist or allergist for most indications.

Step Therapy in Pennsylvania

Pennsylvania enacted a step therapy reform law (Act 53 of 2019) that requires insurers to grant step therapy exceptions when the required drug is contraindicated, has caused an adverse reaction in the patient, or when the patient's condition is expected to worsen on the step therapy drug. If your prescriber can document any of these, Geisinger must grant an exception. Pennsylvania Insurance Department step therapy guidance

PA for Non-Dermatology Indications

For asthma, PA criteria generally require an eosinophil count of 150 cells/mcL or higher, or fractional exhaled nitric oxide (FeNO) of 25 ppb or higher, along with documented uncontrolled moderate-to-severe asthma on inhaled corticosteroids. In the LIBERTY ASTHMA QUEST trial (N=1,902), dupilumab 200 mg or 300 mg every two weeks reduced annualized severe exacerbation rates by 47.7% versus placebo in patients with baseline eosinophils of 300 cells/mcL or higher. PubMed PMID 30552026 Presenting this data point in a PA letter strengthens the clinical argument.

How to Submit a Prior Authorization to Geisinger

The PA submission process has defined steps. Missing documentation is the most common reason for initial denial, so completeness matters more than speed.

Step 1: Gather Clinical Documentation

Your dermatologist or specialist needs to compile:

1. Diagnosis codes (ICD-10-CM L20.9 for atopic dermatitis, J45.51 for moderate persistent asthma, etc.).
2. Dated chart notes showing disease severity scoring.
3. Records of prior therapy trials with dates, doses, durations, and outcomes.
4. Any contraindication documentation for step therapy drugs.
5. Lab results (eosinophil counts, IgE levels) if the indication requires them.

Step 2: Submit Through Geisinger's Provider Portal or Phone Line

Prescribers submit PAs through Geisinger's online portal or by calling the Provider Services line listed on the member's insurance card. Geisinger uses CoverMyMeds and similar electronic PA platforms for many specialty drugs. Urgent requests (when the standard timeline would seriously jeopardize health) must be decided within 72 hours under federal managed care standards set by CMS. CMS Managed Care Rule 42 CFR 438.210

Step 3: Await the Decision

Standard (non-urgent) PA decisions must be made within 3 business days for outpatient drugs under most plan rules. If Geisinger denies, the denial letter must include the specific clinical reason and cite the criteria used.

What Happens After a Denial?

A denial is not the end of the road. Roughly 40-60% of specialty drug PA denials are overturned on appeal when the appeal includes additional clinical documentation, according to analyses of state external review data. Kaiser Family Foundation analysis of insurer denials

Internal Appeal

File an internal appeal within the timeframe stated in the denial letter (usually 60-180 days). The appeal should include a detailed physician letter explaining why the denied drug is medically necessary, peer-reviewed references (cite the SOLO trials, the QUEST trial, or the relevant guideline), and any patient-specific factors the original PA reviewer may have missed.

External Appeal (Independent Review Organization)

If Geisinger upholds the denial after internal appeal, Pennsylvania law entitles members to an external review by an Independent Review Organization (IRO). The IRO decision is binding on the insurer. Pennsylvania's external review process is administered through the Pennsylvania Insurance Department. External reviews for urgent cases must be decided within 72 hours; standard cases within 45 days.

Peer-to-Peer Review

Before or during the appeal, the prescribing physician can request a peer-to-peer review call with Geisinger's medical director. This call gives the clinician a direct opportunity to present the case. Peer-to-peer reviews overturn denials more often than written appeals alone in clinical practice, though published data on exact overturn rates by plan are not publicly available.

Reducing Out-of-Pocket Costs for Dupixent

Even with coverage, cost-sharing can be significant. Several programs reduce what members actually pay.

Dupixent MyWay Savings Program

Sanofi and Regeneron operate the Dupixent MyWay savings program. Commercially insured patients who qualify may pay as little as $0 per month. The program does not apply to patients covered by federal programs (Medicare, Medicaid, TRICARE), because federal anti-kickback statutes prohibit manufacturer copay assistance for government-insured patients. Dupixent MyWay program information via FDA context on manufacturer assistance programs

Patient Assistance Program (PAP)

Uninsured patients or those who cannot afford their cost-share may qualify for Sanofi's patient assistance program, which provides Dupixent at no cost. Income thresholds and eligibility requirements apply.

State Pharmaceutical Assistance Programs

Pennsylvania's PACE (Pharmaceutical Assistance Contract for the Elderly) and PACENET programs help Medicare beneficiaries with limited incomes cover drug costs not paid by Part D. Geisinger Medicare Advantage members can check eligibility through the Pennsylvania Department of Aging.

Dupixent for Pediatric Patients: Specific Coverage Notes

Coverage for pediatric indications deserves separate attention because age-based approval expansions have outpaced some plan formularies.

FDA Approvals in Children

The FDA approved dupilumab for atopic dermatitis in children aged 6 months to 5 years in May 2023 at weight-based dosing. For children 6 to 11 years, approval came in 2020. These are relatively recent expansions. FDA pediatric dupilumab approval

Pediatric PA Considerations

Geisinger pediatric PA criteria mirror the adult criteria but adjust for age-appropriate step therapy agents. Topical tacrolimus (Protopic) and pimecrolimus (Elidel) are commonly required as prior therapy in children because long-term topical corticosteroid use carries growth-restriction concerns in pediatric patients. A 2021 analysis in JAMA Dermatology found that children with severe atopic dermatitis had significantly higher rates of school absenteeism, sleep disruption, and anxiety than healthy controls, data that can support medical necessity arguments. PubMed PMID 33090186

Dupixent for COPD: The Newest Indication and Coverage Uncertainty

In September 2024, the FDA approved dupilumab as an add-on maintenance treatment for adults with uncontrolled COPD with type-2 inflammation (blood eosinophils of 300 cells/mcL or higher). This is the most recent label expansion, and many plan formularies have not yet updated their PA criteria. FDA COPD approval dupilumab

BOREAS and NOTUS Trials

In the BOREAS trial (N=939), dupilumab 300 mg every two weeks reduced moderate-to-severe COPD exacerbation rates by 30% versus placebo at 52 weeks (P<0.001) in patients with eosinophils of 300 cells/mcL or higher. PubMed PMID 38252526 The NOTUS trial (N=935) confirmed a 34% reduction in exacerbations. PubMed PMID 38785241 These two trials form the evidentiary basis for the COPD indication.

Coverage Lag for New Indications

Plans typically take 3-12 months to update formulary PA criteria after an FDA approval. If Geisinger's COPD criteria are not yet established, the prescriber may need to request a coverage exception citing the FDA label directly and submitting the BOREAS/NOTUS data. An absence of explicit PA criteria does not mean the drug is not covered; it may mean the plan defaults to requiring medical necessity documentation.

HealthRX PA Readiness Checklist for Dupixent (Geisinger)

Use this checklist before submitting a prior authorization to Geisinger Health Plan. A complete submission on the first attempt reduces denial rates.

Diagnosis documentation

• Confirmed ICD-10 diagnosis code included in the PA form.
• Disease severity score (IGA, EASI, SCORAD, ACQ, or eosinophil count) documented within the past 6 months.
• Severity score meets the plan's threshold (IGA ≥3 or EASI ≥16 for atopic dermatitis).

Step therapy documentation

• Names, doses, durations, and outcomes of all prior topical or systemic therapies listed chronologically.
• If step therapy is contraindicated, prescriber letter explicitly states the contraindication with clinical rationale.
• Pennsylvania Act 53 exception language included if applicable.

Prescriber qualifications

• PA submitted by or referencing a board-certified dermatologist, allergist, or pulmonologist (depending on indication).

Supporting clinical references

• At least one citation to an FDA-approved indication or AAD/GINA/ATS guideline.
• Relevant trial data (SOLO 1/2, QUEST, BOREAS) referenced in the cover letter.

Administrative completeness

• Member ID, date of birth, and plan group number on every page.
• Correct specialty pharmacy designated (verify with Geisinger's specialty pharmacy network list).
• Urgent flag requested if clinical deterioration is ongoing.

Frequently Asked Questions